Betamethasone Dipropionate
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Corticosteroid-responsive dermatoses (inflammatory and pruritic manifestations) | ≥13 years (augmented); ≥12 years (regular cream/ointment/lotion) | Short-term topical monotherapy | FDA Approved |
| Mild to moderate plaque psoriasis (spray formulation) | Adults ≥18 years | Topical monotherapy (up to 4 weeks) | FDA Approved |
Betamethasone dipropionate is a synthetic fluorinated corticosteroid available in both regular and augmented formulations. The augmented vehicle enhances percutaneous penetration, placing these products in the super-high potency range (US Class I for ointment/gel; Class II for cream/lotion), while regular formulations fall in the high to medium-high potency range (US Class II for ointment; Class III for cream). This vehicle-dependent potency distinction is clinically important and should guide formulation selection. Like other high-potency topical corticosteroids, betamethasone dipropionate is intended for short-term use and should not be applied to the face, groin, or axillae unless specifically directed.
Psoriasis (in combination with calcipotriol) — Evidence quality: High. The fixed-dose combination of calcipotriol 0.005% / betamethasone dipropionate 0.05% (Taclonex/Enstilar) is FDA-approved separately and is among the most widely prescribed topical psoriasis treatments.
Alopecia areata — Evidence quality: Moderate. Used as a topical monotherapy for limited patchy alopecia areata, particularly on the scalp.
Vitiligo (adjunctive) — Evidence quality: Low-Moderate. May promote repigmentation in limited vitiligo, particularly when combined with phototherapy.
Phimosis (topical treatment in children) — Evidence quality: Moderate. Betamethasone 0.05% cream applied to the tight foreskin for 4–8 weeks is an established non-surgical treatment for phimosis in pediatric patients, with success rates of 65–95% in published series.
Dosing
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Moderate-severe dermatoses (body/limbs) — augmented formulations | Thin film once or twice daily | Same; step down once controlled | 50 g/week; max 2 weeks | Augmented ointment/gel = super-high potency (Class I); augmented cream/lotion = high potency (Class II) Do not use with occlusive dressings unless directed |
| Moderate dermatoses (body/limbs) — regular formulations | Thin film once to three times daily | Once or twice daily usually effective | Per clinical judgment; avoid prolonged use | Regular ointment = high potency (Class II); regular cream = medium-high (Class III) Less stringent duration limits than augmented, but still short-term preferred |
| Scalp psoriasis — augmented lotion or spray | A few drops (lotion) or spray BID | Same; reassess at 2 weeks | 50 mL/week; max 2 weeks (lotion); up to 4 weeks (spray) | Massage lotion gently into scalp; spray formulation applied BID for up to 4 weeks Augmented lotion is super-high potency |
| Eczema/atopic dermatitis flare — short-term rescue | Thin film BID (augmented cream preferred) | Step down to mid-potency steroid within 2 weeks | 45–50 g/week; max 2 weeks | Avoid face, flexures, groin; transition to maintenance with lower-potency agent or calcineurin inhibitor Augmented cream (Diprolene AF): max 45 g/week per PI |
The term “augmented” refers to optimized vehicles that enhance drug penetration into the stratum corneum. Augmented betamethasone dipropionate ointment and gel reach super-high potency (Class I), matching clobetasol propionate in vasoconstrictor assays. The augmented cream and lotion are slightly less potent (Class II). Regular (non-augmented) betamethasone dipropionate cream is a medium-high potency product (Class III), suitable for larger body areas or less severe disease. Clinicians should be aware that writing “betamethasone dipropionate 0.05% cream” without specifying augmented vs. regular will result in the pharmacy dispensing whichever is available, which could be a significantly different potency product.
Pharmacology
Mechanism of Action
Betamethasone dipropionate is the 17,21-dipropionate ester of betamethasone, a synthetic fluorinated analog of prednisolone. It possesses high glucocorticoid activity and slight mineralocorticoid activity. As with all topical corticosteroids, betamethasone dipropionate acts by binding to intracellular glucocorticoid receptors, forming a ligand-receptor complex that translocates to the nucleus to modulate gene transcription. This suppresses the synthesis of pro-inflammatory mediators by inducing lipocortin (phospholipase A2 inhibitor), reducing prostaglandin and leukotriene production, and inhibiting NF-kappa B-mediated cytokine transcription (including IL-1, IL-6, TNF-alpha).
The clinical effects include potent anti-inflammatory, antipruritic, and vasoconstrictive activity. The dipropionate ester enhances lipophilicity and skin penetration compared to betamethasone valerate, contributing to its higher potency classification. The augmented vehicles further optimize drug delivery to the target tissue by enhancing solubility and partitioning into the stratum corneum.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Percutaneous; limited from intact skin. Enhanced by inflammation, barrier disruption, occlusion, and augmented vehicle. No formal PK studies conducted for most topical formulations (FDA PI). | Augmented formulations achieve higher local drug concentrations. Diseased skin absorbs significantly more. The 50 g/week and 2-week limits exist specifically to control systemic exposure. |
| Distribution | Bound to plasma proteins in varying degrees (like systemic corticosteroids). Concentrates in the epidermis and dermis at the site of application. | Systemic distribution is undesirable; local concentration drives therapeutic effect. |
| Metabolism | Once absorbed, metabolized primarily in the liver via standard corticosteroid metabolic pathways. Systemic betamethasone half-life: 36–54 hours. | The relatively long systemic half-life of betamethasone means that absorbed drug persists longer than shorter-acting corticosteroids, contributing to HPA axis suppression risk. |
| Elimination | Excreted by kidneys (urine) and in bile. | No dose adjustment needed for renal or hepatic impairment at standard topical doses. Liver failure listed as risk factor for increased HPA suppression in FDA PI. |
Side Effects
Adverse reactions are predominantly local and relate to corticosteroid potency and duration of use. Rates below are from FDA-approved prescribing information for the augmented gel (controlled clinical trials), augmented ointment/lotion, and regular cream formulations.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Total adverse events (augmented gel) | 10% | Combined incidence of all local adverse events in controlled trials of the augmented gel formulation |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Stinging / Burning (augmented gel) | 6% | Most common single AE in augmented gel trials; transient; self-limiting |
| Dry skin (augmented gel) | 4% | More common with gel vehicle; use emollient between applications |
| Pruritus (augmented gel) | 2% | May indicate developing sensitization or irritant response; distinguish from underlying condition |
| Stinging (augmented cream, adults) | 0.4% | Only AE reported as possibly related in adult controlled trials of augmented cream (1/242) |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Erythema | <1% | Reported in augmented ointment and lotion clinical trials |
| Folliculitis | <1% | Steroid folliculitis; more likely on trunk and under occlusion |
| Pruritus | <1% | As above |
| Vesiculation | <1% | Rare; may indicate contact sensitivity to vehicle component |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| HPA axis suppression | Common with extended use: 23–32% in children <12 yr; 2/11 adults (augmented lotion) | 1–3 weeks with large-area or pediatric use | Withdraw drug gradually; reduce frequency or switch to lower potency; ACTH stimulation test to confirm; recovery generally prompt on discontinuation |
| Cushing’s syndrome (iatrogenic) | Rare (prolonged overuse) | Weeks to months of excessive use | Discontinue; endocrinology referral; taper with systemic steroid replacement as needed |
| Skin atrophy (including irreversible) | Pediatric: 5–33% (age-dependent); adults: uncommon with short courses | Weeks; faster on face/flexures | Discontinue; partial recovery possible over months; striae are permanent |
| Cataracts / Glaucoma / Increased IOP | Rare; risk with periocular use | Weeks to months | Avoid periocular application; ophthalmology referral for visual symptoms |
| Allergic contact dermatitis | Rare | Days to weeks | Suspect if condition worsens; patch test; switch vehicle or class |
In open-label pediatric studies of betamethasone dipropionate ointment 0.05%, facial cutaneous atrophy occurred in 17% of infants, 22% of 2–5 year olds, and 33% of 6–8 year olds. Non-facial atrophy ranged from 8–15% across age groups. Across formulations, HPA axis suppression was documented in 23–32% of evaluable children under 12 years. These data underline why betamethasone dipropionate is not recommended in pediatric patients under 12–13 years depending on formulation (FDA PI).
Drug Interactions
Betamethasone dipropionate has minimal systemic absorption under normal conditions, making pharmacokinetic interactions unlikely. Relevant interactions are pharmacodynamic.
Monitoring
Routine laboratory monitoring is not needed for short courses on limited areas. With augmented formulations, extended use, or pediatric patients, clinical and biochemical monitoring for HPA suppression should be considered.
- HPA Axis FunctionIf use exceeds 2 weeks or large BSA
Trigger-BasedACTH stimulation test, morning cortisol, or urinary free cortisol. In HPA studies, augmented ointment at 14 g/day caused transient suppression in psoriasis patients; at 7 g/day for 2–3 weeks, minimal inhibition was noted. In pediatric studies, HPA suppression ranged from 23% (regular cream) to 73% (regular lotion) in children under 12. - Skin IntegrityEvery visit
RoutineInspect for atrophy (thinning, shininess, bruising, loss of skin markings), striae, telangiectasia. Pediatric data show facial atrophy in 17–33% of children depending on age group. Some changes may be irreversible. - Treatment DurationEvery visit
RoutineAugmented formulations: confirm ≤2 consecutive weeks and ≤50 g/week. Reassess if no improvement at 2 weeks. Regular formulations have less strict limits but short-term use remains preferred. - Growth (pediatric)If recurrent or prolonged use
Trigger-BasedMonitor growth velocity in adolescents on betamethasone dipropionate. Children absorb proportionally larger amounts and are more susceptible to systemic effects including growth suppression. - Ocular SymptomsIf applied near eyes
Trigger-BasedRisk of cataracts, glaucoma, and central serous chorioretinopathy with periocular use. Avoid contact with eyes. Ophthalmology referral if visual symptoms develop. - Secondary InfectionEvery visit
RoutineMonitor for bacterial, fungal, or viral superinfection. Treat infection before continuing corticosteroid. Consider tinea incognito if condition worsens despite treatment.
Contraindications & Cautions
Absolute Contraindications
- Hypersensitivity to betamethasone dipropionate, other corticosteroids, or any ingredient in the formulation.
Relative Contraindications (Specialist Input Recommended)
- Rosacea and perioral dermatitis — Betamethasone dipropionate should not be used to treat these conditions; potent topical steroids cause exacerbation and steroid dependence.
- Application to the face, groin, or axillae — Augmented formulations are explicitly labeled to avoid these areas. Thin skin absorbs more drug, increasing atrophy and HPA risk.
- Pregnancy — Betamethasone dipropionate was teratogenic in rabbits at IM doses of 0.05 mg/kg (umbilical hernias, cephalocele, cleft palate). Use on the smallest area for the shortest time if benefit outweighs risk. Dispensing >300 g of potent topical corticosteroid during pregnancy was associated with low birthweight in observational studies.
Use with Caution
- Pediatric patients — Not recommended under 13 years (augmented) or 12 years (regular). Children exhibit higher rates of HPA suppression and skin atrophy due to greater BSA-to-mass ratio.
- Occlusive dressings — Substantially increase absorption; augmented formulations should not be used under occlusion unless directed.
- Existing skin atrophy — Do not apply if atrophy is already present at the treatment site.
- Diaper area — Diapers and plastic pants constitute occlusive dressings; avoid use in the diaper area.
- Lactation — Unknown if topical betamethasone enters breast milk. Apply to smallest area for shortest time. Do not apply directly to the nipple and areola.
Betamethasone dipropionate augmented formulations are super-high potency topical corticosteroids that can produce reversible HPA axis suppression with the potential for glucocorticosteroid insufficiency during or after treatment withdrawal. Treatment with augmented formulations should be limited to 2 consecutive weeks, with no more than 50 g (or 50 mL) per week. Cushing’s syndrome, hyperglycemia, and glucosuria may occur with prolonged exposure to excessive doses. Pediatric patients are more susceptible to systemic toxicity from topical corticosteroids due to their larger skin surface area relative to body mass.
Patient Counselling
Purpose of Therapy
Betamethasone dipropionate is a strong prescription steroid applied to the skin to reduce inflammation, redness, itching, and swelling from skin conditions such as eczema and psoriasis. It is intended for short-term use only and should be discontinued once the condition is controlled.
How to Take
Apply a thin layer to the affected area only, once or twice daily as directed. Rub in gently and completely. Wash hands after application unless the hands are the treatment site. Do not bandage or cover the treated area unless instructed. Do not use more than the prescribed amount.
Sources
- Diprolene (betamethasone dipropionate) Ointment, 0.05% (Augmented) — Full Prescribing Information. FDA Label (2019)Primary source for augmented ointment HPA data (minimal inhibition at 7 g/day for 2–3 weeks; suppression at 14 g/day), dosing limits (50 g/week, 2 weeks max), teratogenicity (rabbits IM 0.05 mg/kg), and ophthalmic adverse reaction warnings.
- Diprolene AF (betamethasone dipropionate) Cream, 0.05% (Augmented) — Full Prescribing Information. FDA Label (2014)Source for augmented cream AE rate (stinging 0.4%), HPA data (cortisol lowering at 7 g/day for 1 week), max 45 g/week, and pediatric HPA suppression data (19/60 = 32%).
- Betamethasone Dipropionate Gel (Augmented), 0.05% — Full Prescribing Information. DailyMedSource for augmented gel adverse reaction incidences (total 10%: stinging 6%, dry skin 4%, pruritus 2%) and HPA inhibition at 7 g/day in psoriasis/AD patients.
- Betamethasone Dipropionate Cream USP, 0.05% (Regular) — Full Prescribing Information. DailyMedSource for regular cream pediatric HPA data (10/43 = 23% in children 2–12 years) and pediatric skin atrophy incidence (5% in one trial).
- Betamethasone Dipropionate Ointment USP, 0.05% (Regular) — Full Prescribing Information. DailyMedSource for regular ointment pediatric HPA data (15/53 = 28% in children 6 mo–12 years) and detailed pediatric skin atrophy rates by age group (facial atrophy 17–33%).
- Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54(1):1-15. DOI: 10.1016/j.jaad.2005.01.010Comprehensive review of local and systemic AEs of topical corticosteroids including HPA suppression, skin atrophy, and ocular complications relevant to betamethasone dipropionate.
- Tadicherla S, Ross K, Shenefelt PD, Fenske NA. Topical corticosteroids in dermatology. J Drugs Dermatol. 2009;8(12):1093-1105. PubMed: 20027937Practical review of topical corticosteroid selection, vehicle effects on potency, and prescribing strategies including the regular vs. augmented vehicle distinction.
- Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: Section 2. J Am Acad Dermatol. 2014;71(1):116-132. DOI: 10.1016/j.jaad.2014.03.023AAD guideline on topical corticosteroid selection by potency and body site for atopic dermatitis management.
- Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 3. J Am Acad Dermatol. 2009;60(4):643-659. DOI: 10.1016/j.jaad.2008.12.032AAD guideline positioning topical corticosteroids in psoriasis management and discussing combination with vitamin D analogs.
- Schoepe S, Schacke H, May E, Asadullah K. Glucocorticoid therapy-induced skin atrophy. Exp Dermatol. 2006;15(6):406-420. DOI: 10.1111/j.0906-6705.2006.00435.xDetailed review of mechanisms underlying corticosteroid-induced skin atrophy including collagen degradation, particularly relevant to high-potency agents like betamethasone dipropionate.
- Duong TV, et al. Characterizing local and systemic exposure to clobetasol propionate in healthy subjects and patients with atopic dermatitis. Br J Clin Pharmacol. 2025. DOI: 10.1002/bcp.70102PBPK modeling study for super-potent topical corticosteroids demonstrating that systemic exposure increases with impaired barrier and BSA; principles apply to augmented betamethasone dipropionate.
- Stacey SK, McEleney M. Topical corticosteroids: choice and application. Am Fam Physician. 2021;103(6):337-343. PubMed: 33719380Practical overview of topical corticosteroid potency classification, fingertip unit dosing, and the vehicle-dependent potency differences relevant to betamethasone dipropionate prescribing.
- Wood Heickman LK, Davallow Ghajar L, Conaway M, Rogol AD. Evaluation of HPA axis suppression following cutaneous use of topical corticosteroids in children: a meta-analysis. Horm Res Paediatr. 2018;89(6):389-396. DOI: 10.1159/000489125Meta-analysis quantifying HPA axis suppression risk in pediatric patients using topical corticosteroids, supporting the age-based restrictions for betamethasone dipropionate.